Key predictors, including higher APACHE II scores, longer durations of intravenous corticosteroid use, elevated CMV IgG titers, lower CD4+ lymphocyte counts, and histories of chronic kidney disease or organ transplantation, were associated with increased predicted probabilities of CMV reactivation. Here, CD4 is linked to chronic kidney disease.